TG THERAPEUTICS, INC. (TGTX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$62.00

From 52W high+0.00%

Volume1.85M

Market cap$9.43B

P/E (TTM)20.2x

P/S (TTM)11.8x

Div yield—

Key dataNov 4, 2026

Open

$62.00

From 52W high

+0.00%

Volume

1.85M

Market cap

$9.43B

ValuationView details →

P/E (Fwd)

26.9x

EV/EBITDA

71.8x

P/E (TTM)

20.2x

RSI (14)

68.8

MomentumView details →

1D Return

+1.45%

YTD Return

+107.84%

SummaryUpdated Jun 1, 2026

TG Therapeutics, Inc. (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company founded in 1993 and headquartered in New York. The company focuses on developing and commercializing treatments for B-cell malignancies and autoimmune diseases. After decades of research and development, TG Therapeutics achieved its first major commercial milestone in December 2022 with FDA approval of <b>BRIUMVI</b>, a novel treatment for relapsing forms of multiple sclerosis. The company has since transitioned from a pure development-stage biotech to a commercial enterprise with significant revenue growth, generating over $329 million in 2024.

Ask drillr about TG THERAPEUTICS, INC. →

ValuationView details →

P/E (Fwd)

26.9x

P/E (TTM)

20.2x

EV/EBITDA

71.8x

EV/Sales

12.1x

P/S (TTM)

11.8x

P/B (TTM)

15.6x

ProfitabilityView details →

Gross Margin

82.36%

Net Margin

55.22%

EBITDA Margin

16.79%

ROE (TTM)

73.08%

ROA (TTM)

26.93%

Asset Turnover

0.50x

GrowthView details →

Revenue YoY

+76.08%

EPS YoY

+634.60%

FCF YoY

+129.35%

Revenue CAGR 3Y

+504.86%

EPS CAGR 3Y

+489.19%

EBITDA YoY

+37.40%

MomentumView details →

1D Return

+1.45%

YTD Return

+107.84%

1Y Return

+82.01%

RSI (14)

68.8

vs 50D SMA

+11.29%

vs 200D SMA

+39.98%

Capital & dividendView details →

Debt/Equity

1.25x

Current Ratio

4.27x

Quick Ratio

3.72x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.05

EPS Surprise

−83.64%

Beats (12Q)

5/12

Next Q EPS Est

$0.45

Avg Surprise (4Q)

−29.56%

Rev Surprise

4.60%

Financials snapshotView financials →

Revenue (TTM)

799.54M

Net Income (TTM)

441.49M

Op. CF (TTM)

17.88M

Next earningsNov 9, 2026 →

Latest newsMore news →

TG THERAPEUTICS, INC. announced publication of a five-year comparative analysis of BRIUMVI versus ocrelizumab and ofatumumab in relapsing multiple sclerosis.23d ago

TG Therapeutics announced the schedule of data presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, including a late-breaking oral presentation on initial Phase 1 results for azer-cel in patients with primary progressive multiple sclerosis and several presentations on BRIUMVI.27d ago

Similar companies

Spyre Therapeutics, Inc.SYRE ImmunityBio, Inc.IBRX Caris Life Sciences, Inc.CAI Madrigal Pharmaceuticals, Inc.MDGL Protagonist Therapeutics, Inc.PTGX Krystal Biotech, Inc.KRYS Find similar companies →

Latest newsMore news →

TG THERAPEUTICS, INC. announced publication of a five-year comparative analysis of BRIUMVI versus ocrelizumab and ofatumumab in relapsing multiple sclerosis.23d ago TG Therapeutics announced the schedule of data presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, including a late-breaking oral presentation on initial Phase 1 results for azer-cel in patients with primary progressive multiple sclerosis and several presentations on BRIUMVI.27d ago Kuehn Law, PLLC is investigating whether certain officers and directors of TG Therapeutics, Inc. breached their fiduciary duties to shareholders.37d ago